Company Profile

Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry. With a market value of $7 billion, Jafron has three branches, 11 subsidiaries, one sub-subsidiary and medical foundation, insurance, etc.

Jafron has diligently devoted to the R&D, production and sales of blood purification products primarily in the hemoadsorption field for decades. It is dedicated to providing professional services to patients worldwide, covering ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, etc.

The company set 183 offices in China and five global service centers, including Vietnam, Europe, South America, etc., with a professional therapy-providing team of over 1,100 staff and 1,000 partners. With more than 20-years of clinical experience, the company's flagship product, "HA series disposable hemoperfusion cartridge," originally developed by Jafron, has been adopted in more than 8,000 key hospitals across 80 countries and regions, with 5 million cases of clinical application annually.

As a global adsorption therapies provider, Jafron is involved in all aspects of exploring solutions for disease, from research and development of new hemoperfusion therapies to manufacturing our hemoadsorption products, right through to offering comprehensive therapy options. Jafron will not rest in its effort to explore novel medical fields to save lives, improve patients' quality of life, and realize the vision of "Health Technology for a better world."

Main products

HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, Hemoperfusion Machine and Blood Purification Machine, etc.

Company Profile

Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry. With a market value of $7 billion, Jafron has three branches, 11 subsidiaries, one sub-subsidiary and medical foundation, insurance, etc.

Jafron has diligently devoted to the R&D, production and sales of blood purification products primarily in the hemoadsorption field for decades. It is dedicated to providing professional services to patients worldwide, covering ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, etc.

The company set 183 offices in China and five global service centers, including Vietnam, Europe, South America, etc., with a professional therapy-providing team of over 1,100 staff and 1,000 partners. With more than 20-years of clinical experience, the company's flagship product, "HA series disposable hemoperfusion cartridge," originally developed by Jafron, has been adopted in more than 8,000 key hospitals across 80 countries and regions, with 5 million cases of clinical application annually.

As a global adsorption therapies provider, Jafron is involved in all aspects of exploring solutions for disease, from research and development of new hemoperfusion therapies to manufacturing our hemoadsorption products, right through to offering comprehensive therapy options. Jafron will not rest in its effort to explore novel medical fields to save lives, improve patients' quality of life, and realize the vision of "Health Technology for a better world."

Main products

HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, Hemoperfusion Machine and Blood Purification Machine, etc.

Dong Fan
Chairman of the Board

Dong Fan, currently chairman, president, and chief executive officer of Jafron, is responsible for its strategic direction, overall performance, and long-term growth plan. He is proficient in business management and marketing with excellent commercial awareness, a sense of technological innovation and market development, and a powerful consciousness and ability to combine social resources.

Mr. Dong graduated from the Shanghai University of Finance and Economics with a bachelor's degree in trade and economics in 1992, graduated from Sun Yet-Sen University with a master's degree in business management. Prior to steering Jafron in 1989, Mr. Dong was engaged in marketing and management in Livzon Pharmaceutical Group Co., Ltd.

Dong Fan
Chairman of the Board

Dong Fan, currently chairman, president, and chief executive officer of Jafron, is responsible for its strategic direction, overall performance, and long-term growth plan. He is proficient in business management and marketing with excellent commercial awareness, a sense of technological innovation and market development, and a powerful consciousness and ability to combine social resources.

Mr. Dong graduated from the Shanghai University of Finance and Economics with a bachelor's degree in trade and economics in 1992, graduated from Sun Yet-Sen University with a master's degree in business management. Prior to steering Jafron in 1989, Mr. Dong was engaged in marketing and management in Livzon Pharmaceutical Group Co., Ltd.

Headquarter

Our History

  • 2021

    2021

    Jafron established the MOST (Multi-organ Support Therapy) Global Advisory Board, which includes the world's top medical experts in clinical research and critical care medicine.

  • 2020

    2020

    Jafron hemoperfusion technology was included in 11 national medical manuals and recommendations for the treatment of Covid-19.

  • 2018

    2018

    The Multi-Center RCT Research of HA130 Hemoperfusion Cartridge was completed and obtained significant achievements.

  • 2016

    2016

    Jafron was listed on the A-share market.
    Jafron launched DPMAS technology which was incorporated into the "Artificial Liver Treatment Guidelines."

  • 2012

    2012

    BS Disposable Plasma Bilirubin Perfusion Adsorption Column for hepatopathy was launched.

  • 2011

    2011

    ● Jafron successively owned CE Certification, ISO International Quality Certification, and China GMP National Certification.
    ● Jafron was listed in Forbes of Potential Chinese Enterprises and honored with "Key Hi-Tech Enterprise of National Torch Program."

  • 2009

    2009

    Jafron won the National Scientific and Technological Progress Award prize, the top-level technological award in China.

  • 2007

    2007

    Jafron Hemoperfusion Machine and Blood Pump were available to the public.

  • 2005

    2005

    DNA Immunoadsorption Column for the immune disease was launched.

  • 2004

    2004

    Jafron invented HA130 Disposable Hemoperfusion Cartridge for end-stage renal disease (ESRD) patients.

  • 1989

    1989

    Company was founded.

Our History

  • 2021

    2021

    Jafron established the MOST (Multi-organ Support Therapy) Global Advisory Board, which includes the world's top medical experts in clinical research and critical care medicine.

  • 2020

    2020

    Jafron hemoperfusion technology was included in 11 national medical manuals and recommendations for the treatment of Covid-19.

  • 2018

    2018

    The Multi-Center RCT Research of HA130 Hemoperfusion Cartridge was completed and obtained significant achievements.

  • 2016

    2016

    Jafron was listed on the A-share market.
    Jafron launched DPMAS technology which was incorporated into the "Artificial Liver Treatment Guidelines."

  • 2012

    2012

    BS Disposable Plasma Bilirubin Perfusion Adsorption Column for hepatopathy was launched.

  • 2011

    2011

    ● Jafron successively owned CE Certification, ISO International Quality Certification, and China GMP National Certification.
    ● Jafron was listed in Forbes of Potential Chinese Enterprises and honored with "Key Hi-Tech Enterprise of National Torch Program."

  • 2009

    2009

    Jafron won the National Scientific and Technological Progress Award prize, the top-level technological award in China.

  • 2007

    2007

    Jafron Hemoperfusion Machine and Blood Pump were available to the public.

  • 2005

    2005

    DNA Immunoadsorption Column for the immune disease was launched.

  • 2004

    2004

    Jafron invented HA130 Disposable Hemoperfusion Cartridge for end-stage renal disease (ESRD) patients.

  • 1989

    1989

    Company was founded.